Date: 2013-08-30
Type of information: Collaboration agreement
Compound: OncoDEEP DX cancer panel
Company: OncoDNA (Belgium) Integrated BioBank of Luxembourg - IBBL (Luxembourg)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism: OncoDEEP® DX is OncoDNA\'s routine cancer test, with all the genes linked to targeted cancer treatments currently on the market, i.e. with a Marketing Authorisation Application (MAA) in Europe. This targeted sequencing of 40 genes is done on an Ion Torrent sequencing platform and can detect both point mutations (SNPs) and small insertions and deletions. The genes OncoDNA chooses are the ones directly linked to the treatment but in some cases the company also include genes of the pathway concerned (upstream and downstream of the gene). The test includes bioinformatic and clinical analyses, and the doctor receives, or can see on the Internet, a detailed molecular analysis of the tumour with the link to therapies currently on the market. OncoDNA archives the data and also provides an automatic update of the status of the mutations discovered in the tumour.
Disease:
Details: * On August 30, 2013, OncoDNA, a Belgium based company providing DNA next generation sequencing (NGS) tests for clinical use in cancer, has announced a collaboration agreement with IBBL (Integrated BioBank of Luxembourg). IBBL has chosen OncoDNA as its preferred supplier of clinical grade molecular diagnostics for lung cancer, using the OncoDEEP DX cancer panel. This collaboration agreement with OncoDNA will enable Luxembourg physicians to access medical innovations based on next gensequencing providing them with clinically relevant interpretations of patients\' tumours.
OncoDNA is a subsidiary of Bio.Be, an affiliated company of IPG (Institute of Pathology and Genetics) in Belgium.
Financial terms:
Latest news:
